NEW YORK – The second phase of an Irish precision oncology consortium launched this week with €28 million ($32.5 million) in funding to advance a sweeping range of projects, including promising ...

NEW YORK – Swiss radiopharmaceutical company Nuclidium is planning to test its copper-61-based theranostic in SSTR2-positive breast cancer after a Phase I/II study showed its efficacy in imaging ...

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

Previously the agency recommended doctors only discuss the risk of adverse events from chemotherapy for those with DPD deficiency.

Rare Therapeutics will specifically advance gene therapies for extremely rare diseases with a goal of making them accessible globally.

NEW YORK – Fore Therapeutics' investments in its next-generation BRAF inhibitor plixorafenib seem to be paying off, as the company announced positive results from an interim analysis of its ongoing ...

Although the committee was uncertain about some of the evidence, it found that Lorviqua's cost-effectiveness was an acceptable use of NHS resources.

A retrospective study using data from multiple trials could provide regulators evidence on Ataraxis Breast's ability to predict treatment response.

NEW YORK – Affinia Therapeutics on Tuesday said it will use $40 million raised through a Series C funding round to advance its pipeline of gene therapies for cardiovascular and neurological diseases.

Patients with advanced triple-negative breast cancer who are ineligible for immunotherapy survived longer on Datroway than chemotherapy.

Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid growing healthcare access worries.

Arbor will receive $115 million in upfront and near-term payments and be eligible for up to $2 billion in milestone payments and tiered royalties.